Skip to main content
TIANYU BIO-TECHNOLOGY CO.,LTD. logo

TIANYU BIO-TECHNOLOGY CO.,LTD. — Investor Relations & Filings

Ticker · 603717 ISIN · CNE1000030W1 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,621 across all filing types
Latest filing 2025-12-29 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 603717

About TIANYU BIO-TECHNOLOGY CO.,LTD.

https://www.tianyubiotech.com/

TIANYU BIO-TECHNOLOGY CO.,LTD. specializes in the research, development, and large-scale production of active pharmaceutical ingredients (APIs) and advanced pharmaceutical intermediates. The company focuses on therapeutic areas such as cardiovascular health, diabetes management, and anti-viral treatments. Its core product portfolio includes various sartan-based intermediates and other complex organic synthesis products. TIANYU BIO-TECHNOLOGY emphasizes rigorous quality management systems and adheres to international regulatory standards to ensure product safety and efficacy. By leveraging advanced chemical synthesis technologies and a robust R&D infrastructure, the company provides customized manufacturing solutions and high-quality chemical components to global pharmaceutical partners. Its operations are characterized by a commitment to technical innovation and process optimization in the synthesis of complex molecules.

Recent filings

Filing Released Lang Actions
关于2025年度为合作养殖农户提供担保预计的进展公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the company's provision of guarantees for cooperative farming households, including specifics about the guarantee amount, the guaranteed party, internal decision procedures, and cumulative guarantee amounts. It includes financial figures related to guarantees but does not present comprehensive financial statements or a full financial report. The document is an announcement of a specific financing-related activity (providing guarantees) rather than a full capital or financing update report. Given the nature of the content focusing on guarantee provision and related financial risk disclosures, it fits best under Capital/Financing Update (CAP). The document length is 2525 characters, which is sufficient for a detailed announcement but not a full report. Therefore, the classification is CAP with high confidence.
2025-12-29 Chinese
关于2026年度为合作养殖农户提供担保预计的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Tianyu Bio-Technology Co., Ltd. regarding the expected guarantee amount for cooperative farming households in the year 2026. It details the guarantee objects, amounts, risk control measures, internal decision procedures, and board opinions. The document is structured as a formal announcement with no financial statements or detailed financial analysis. It is not a full financial report, audit report, or earnings release. The document is relatively short (2961 characters) and serves to inform shareholders and the public about the planned guarantee and the need for shareholder approval. This fits the profile of a Regulatory Filing (RNS) as it is a general regulatory announcement about a corporate action (guarantee provision) that requires shareholder approval, but it is not a report or presentation itself.
2025-12-19 Chinese
关于召开2026年第一次临时股东会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice about convening the 2026 first extraordinary general meeting of shareholders (临时股东会通知) for Tianyu Bio-Technology Co., Ltd. It details the meeting date, voting methods, agenda items, and procedural instructions for shareholders. It does not contain financial statements or results but is an announcement related to a shareholders meeting. This fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA) or possibly Proxy Solicitation & Information Statement (PSI). However, since it is a notice of the meeting itself and voting procedures rather than solicitation materials or voting results, it is best classified as a Proxy Solicitation & Information Statement (PSI). The document length is 3112 characters, which is typical for such notices. Therefore, the classification is PSI with high confidence.
2025-12-19 Chinese
关于公司2026年度日常关联交易预计的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from Tianyu Bio-Technology Co., Ltd. regarding the expected daily related-party transactions for the fiscal year 2026. It includes details about the nature of the transactions, the approval process by the board and independent directors, estimated transaction amounts, related party information, and the pricing principles. The document is an announcement about anticipated related-party transactions and their governance, not a full financial report or audit. It is not a full annual or interim report, nor is it a certification or voting result. The document length is about 3,029 characters, which is relatively short and focused on a specific topic. This fits best with a Regulatory Filing (RNS) as it is a regulatory announcement about related-party transactions that does not fit other more specific categories like Annual Report, Audit Report, or Management Reports.
2025-12-19 Chinese
第五届董事会第五次会议决议公告
Board/Management Information Classification · 100% confidence The document is a formal announcement of resolutions passed at the fifth meeting of the fifth board of directors of Tianyu Bio-Technology Co., Ltd. It details the meeting's attendance, the agenda items discussed, and the voting results on various proposals including termination of a fundraising investment project, daily related-party transactions forecast, guarantees for cooperative farmers, and the proposal to convene the first extraordinary general meeting of shareholders in 2026. The document does not contain financial statements or detailed financial data but rather reports on board decisions and meeting outcomes. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the company's board of directors or senior management.
2025-12-19 Chinese
国海证券股份有限公司关于天域生物科技股份有限公司终止募集资金投资项目并将剩余募集资金永久补充流动资金的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed report from Guohai Securities Co., Ltd. regarding the termination of a fundraising investment project by Tianyu Biotechnology Co., Ltd. It includes specifics about the original fundraising, the use of funds, reasons for project termination, and plans to permanently supplement working capital with remaining funds. The document references regulatory compliance with securities issuance and listing rules, and includes audit and supervisory opinions. It is not a brief announcement but a substantive report on the fundraising project status and changes. This fits the category of a Capital/Financing Update (CAP), as it deals with fundraising activities, use of proceeds, and changes in capital allocation.
2025-12-19 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.